FDA grants accelerated approval of mosunetuzumab for relapsed, refractory follicular lymphoma. Nierengarten MB. Cancer 2023;129:1465-1466.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Nierengarten MB. FDA grants accelerated approval of mosunetuzumab for relapsed, refractory follicular lymphoma. Cancer 2023;129:1465-1466.
PMID: 37088993